Once Bayer raises the billions it anticipates from an IPO of its plastics business, it plans to pay off debt. But after that? Expect some OTC acquisitions, the company's CEO says.
The clock is about to strike 6 months since Stryker expressed interest in acquiring Smith & Nephew, only to be dissuaded by a rise in that company's stock price once news of the potential deal broke out. And so begins the speculation that Stryker will actually make a bid on the fellow orthopedics company this time around.
Ohio-headquartered CRO Ricerca Biosciences can put off its liquidation plans, as the company has found an acquirer to keep its doors open just ahead of a self-imposed deadline.
Pet retail giant Petco of San Diego announced Wednesday that it is acquiring online and catalog company Drs. Foster & Smith, which is owned by veterinarians and based in Wisconsin.
The European Commission was scheduled to rule on Zimmer's planned acquisition of fellow orthopedics company Biomet by March 11. Now the deadline has been extended by a "limited number of days," Zimmer says.
Medtronic's fastest growing business is in diabetes, which gained 10% to $430 million in the most recent quarter over a year ago. Now the medical device giant is looking to expand beyond its dominance in Type 1 diabetes that is based on the success of its insulin pump MiniMed. During an earnings call, Medtronic disclosed that it reorganized its diabetes group last quarter.
Valeant CEO J. Michael Pearson upheld his reputation as a disciplined bidder when he refused to top Actavis' $66 billion bid for Allergan. But now that his company has nothing to show for the past 7 months, has its dealmaking reputation taken a hit?
With the excitement over Actavis' white-knight swoop-in for Allergan out of the way, it's time to take a closer look at the transaction--and how it compares with Valeant's proposed Allergan tie-up.
In a deal valued at more than $660 million, Baring Private Equity Asia showed up Monday as the buyer of a Japanese CMO and Tokio Marine Capital as the seller.
With Actavis and Allergan's deal agreement, the Botox maker is getting what it's wanted for months--a way to thwart hostile bidder Valeant. And Actavis? It's getting a glimpse of a future that holds $23 billion in annual revenue, and that would officially punch its ticket into Big Pharma.